Effect of Hypoxia-Inducible Factor-1 alpha Gene Therapy on Walking Performance in Patients With Intermittent Claudication

Mark A. Creager, Jeffrey W. Olin, Jill J. F. Belch, Gregory L. Moneta, Timothy D. Henry, Sanjay Rajagopalan, Brian H. Annex, William R. Hiatt

    Research output: Contribution to journalArticle

    67 Citations (Scopus)

    Abstract

    Background-Hypoxia-inducible factor-1 alpha (HIF-1 alpha) is a transcriptional regulatory factor that orchestrates cellular responses to hypoxia. It increases collateral vessel growth and blood flow in models of hind-limb ischemia. This study tested whether intramuscular administration of Ad2/HIF-1 alpha/VP16, an engineered recombinant type 2 adenovirus vector encoding constitutively active HIF-1 alpha, improves walking time in patients with peripheral artery disease and intermittent claudication.

    Methods and Results-Two hundred eighty-nine patients with claudication were randomized in a double-blind manner to 1 of 3 doses of Ad2/HIF-1 alpha/VP16 (2 x 10(9), 2 x 10(10), or 2 x 10(11) viral particles) or placebo, administered by 20 intramuscular injections to each leg. Graded treadmill tests were performed at baseline and then 3, 6, and 12 months after treatment. The primary end point was the change in peak walking time from baseline to 6 months. The secondary end point was change in claudication onset time, and tertiary end points included changes in ankle-brachial index and quality-of-life assessments. Median peak walking time increased by 0.82 minutes (interquartile range, -0.05-1.93 minutes) in the placebo group and by 0.82 minutes (interquartile range, -0.07-2.12 minutes), 0.28 minutes (interquartile range, -0.37-1.70 minutes), and 0.78 minutes (interquartile range, -0.02-2.10 minutes) in the HIF-1 alpha 2 x 10(9), 2 x 10(10), or 2 x 10(11) viral particle groups, respectively (P = NS between placebo and each HIF-1 alpha treatment group). There were no significant differences in claudication onset time, ankle-brachial index, or quality-of-life measurements between the placebo and each HIF-1 alpha group.

    Conclusions-Gene therapy with intramuscular administration of Ad2/HIF-1 alpha/VP16 is not an effective treatment for patients with intermittent claudication.

    Original languageEnglish
    Pages (from-to)1765-U148
    Number of pages11
    JournalCirculation
    Volume124
    Issue number16
    DOIs
    Publication statusPublished - 18 Oct 2011

    Keywords

    • angiogenesis
    • gene therapy
    • intermittent claudication
    • peripheral vascular diseases
    • CRITICAL LIMB ISCHEMIA
    • ENDOTHELIAL GROWTH-FACTOR
    • PERIPHERAL ARTERIAL-DISEASE
    • DOUBLE-BLIND
    • TRANSCRIPTION FACTOR
    • FACTOR-I
    • ANGIOGENESIS
    • PLACEBO
    • OXYGEN
    • STABILIZATION

    Cite this

    Creager, Mark A. ; Olin, Jeffrey W. ; Belch, Jill J. F. ; Moneta, Gregory L. ; Henry, Timothy D. ; Rajagopalan, Sanjay ; Annex, Brian H. ; Hiatt, William R. / Effect of Hypoxia-Inducible Factor-1 alpha Gene Therapy on Walking Performance in Patients With Intermittent Claudication. In: Circulation. 2011 ; Vol. 124, No. 16. pp. 1765-U148.
    @article{d09ceba44c5c47e7bf757e37e95f5912,
    title = "Effect of Hypoxia-Inducible Factor-1 alpha Gene Therapy on Walking Performance in Patients With Intermittent Claudication",
    abstract = "Background-Hypoxia-inducible factor-1 alpha (HIF-1 alpha) is a transcriptional regulatory factor that orchestrates cellular responses to hypoxia. It increases collateral vessel growth and blood flow in models of hind-limb ischemia. This study tested whether intramuscular administration of Ad2/HIF-1 alpha/VP16, an engineered recombinant type 2 adenovirus vector encoding constitutively active HIF-1 alpha, improves walking time in patients with peripheral artery disease and intermittent claudication.Methods and Results-Two hundred eighty-nine patients with claudication were randomized in a double-blind manner to 1 of 3 doses of Ad2/HIF-1 alpha/VP16 (2 x 10(9), 2 x 10(10), or 2 x 10(11) viral particles) or placebo, administered by 20 intramuscular injections to each leg. Graded treadmill tests were performed at baseline and then 3, 6, and 12 months after treatment. The primary end point was the change in peak walking time from baseline to 6 months. The secondary end point was change in claudication onset time, and tertiary end points included changes in ankle-brachial index and quality-of-life assessments. Median peak walking time increased by 0.82 minutes (interquartile range, -0.05-1.93 minutes) in the placebo group and by 0.82 minutes (interquartile range, -0.07-2.12 minutes), 0.28 minutes (interquartile range, -0.37-1.70 minutes), and 0.78 minutes (interquartile range, -0.02-2.10 minutes) in the HIF-1 alpha 2 x 10(9), 2 x 10(10), or 2 x 10(11) viral particle groups, respectively (P = NS between placebo and each HIF-1 alpha treatment group). There were no significant differences in claudication onset time, ankle-brachial index, or quality-of-life measurements between the placebo and each HIF-1 alpha group.Conclusions-Gene therapy with intramuscular administration of Ad2/HIF-1 alpha/VP16 is not an effective treatment for patients with intermittent claudication.",
    keywords = "angiogenesis, gene therapy, intermittent claudication, peripheral vascular diseases, CRITICAL LIMB ISCHEMIA, ENDOTHELIAL GROWTH-FACTOR, PERIPHERAL ARTERIAL-DISEASE, DOUBLE-BLIND, TRANSCRIPTION FACTOR, FACTOR-I, ANGIOGENESIS, PLACEBO, OXYGEN, STABILIZATION",
    author = "Creager, {Mark A.} and Olin, {Jeffrey W.} and Belch, {Jill J. F.} and Moneta, {Gregory L.} and Henry, {Timothy D.} and Sanjay Rajagopalan and Annex, {Brian H.} and Hiatt, {William R.}",
    year = "2011",
    month = "10",
    day = "18",
    doi = "10.1161/CIRCULATIONAHA.110.009407",
    language = "English",
    volume = "124",
    pages = "1765--U148",
    journal = "Circulation",
    issn = "0009-7322",
    publisher = "American Heart Association",
    number = "16",

    }

    Creager, MA, Olin, JW, Belch, JJF, Moneta, GL, Henry, TD, Rajagopalan, S, Annex, BH & Hiatt, WR 2011, 'Effect of Hypoxia-Inducible Factor-1 alpha Gene Therapy on Walking Performance in Patients With Intermittent Claudication', Circulation, vol. 124, no. 16, pp. 1765-U148. https://doi.org/10.1161/CIRCULATIONAHA.110.009407

    Effect of Hypoxia-Inducible Factor-1 alpha Gene Therapy on Walking Performance in Patients With Intermittent Claudication. / Creager, Mark A.; Olin, Jeffrey W.; Belch, Jill J. F.; Moneta, Gregory L.; Henry, Timothy D.; Rajagopalan, Sanjay; Annex, Brian H.; Hiatt, William R.

    In: Circulation, Vol. 124, No. 16, 18.10.2011, p. 1765-U148.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Effect of Hypoxia-Inducible Factor-1 alpha Gene Therapy on Walking Performance in Patients With Intermittent Claudication

    AU - Creager, Mark A.

    AU - Olin, Jeffrey W.

    AU - Belch, Jill J. F.

    AU - Moneta, Gregory L.

    AU - Henry, Timothy D.

    AU - Rajagopalan, Sanjay

    AU - Annex, Brian H.

    AU - Hiatt, William R.

    PY - 2011/10/18

    Y1 - 2011/10/18

    N2 - Background-Hypoxia-inducible factor-1 alpha (HIF-1 alpha) is a transcriptional regulatory factor that orchestrates cellular responses to hypoxia. It increases collateral vessel growth and blood flow in models of hind-limb ischemia. This study tested whether intramuscular administration of Ad2/HIF-1 alpha/VP16, an engineered recombinant type 2 adenovirus vector encoding constitutively active HIF-1 alpha, improves walking time in patients with peripheral artery disease and intermittent claudication.Methods and Results-Two hundred eighty-nine patients with claudication were randomized in a double-blind manner to 1 of 3 doses of Ad2/HIF-1 alpha/VP16 (2 x 10(9), 2 x 10(10), or 2 x 10(11) viral particles) or placebo, administered by 20 intramuscular injections to each leg. Graded treadmill tests were performed at baseline and then 3, 6, and 12 months after treatment. The primary end point was the change in peak walking time from baseline to 6 months. The secondary end point was change in claudication onset time, and tertiary end points included changes in ankle-brachial index and quality-of-life assessments. Median peak walking time increased by 0.82 minutes (interquartile range, -0.05-1.93 minutes) in the placebo group and by 0.82 minutes (interquartile range, -0.07-2.12 minutes), 0.28 minutes (interquartile range, -0.37-1.70 minutes), and 0.78 minutes (interquartile range, -0.02-2.10 minutes) in the HIF-1 alpha 2 x 10(9), 2 x 10(10), or 2 x 10(11) viral particle groups, respectively (P = NS between placebo and each HIF-1 alpha treatment group). There were no significant differences in claudication onset time, ankle-brachial index, or quality-of-life measurements between the placebo and each HIF-1 alpha group.Conclusions-Gene therapy with intramuscular administration of Ad2/HIF-1 alpha/VP16 is not an effective treatment for patients with intermittent claudication.

    AB - Background-Hypoxia-inducible factor-1 alpha (HIF-1 alpha) is a transcriptional regulatory factor that orchestrates cellular responses to hypoxia. It increases collateral vessel growth and blood flow in models of hind-limb ischemia. This study tested whether intramuscular administration of Ad2/HIF-1 alpha/VP16, an engineered recombinant type 2 adenovirus vector encoding constitutively active HIF-1 alpha, improves walking time in patients with peripheral artery disease and intermittent claudication.Methods and Results-Two hundred eighty-nine patients with claudication were randomized in a double-blind manner to 1 of 3 doses of Ad2/HIF-1 alpha/VP16 (2 x 10(9), 2 x 10(10), or 2 x 10(11) viral particles) or placebo, administered by 20 intramuscular injections to each leg. Graded treadmill tests were performed at baseline and then 3, 6, and 12 months after treatment. The primary end point was the change in peak walking time from baseline to 6 months. The secondary end point was change in claudication onset time, and tertiary end points included changes in ankle-brachial index and quality-of-life assessments. Median peak walking time increased by 0.82 minutes (interquartile range, -0.05-1.93 minutes) in the placebo group and by 0.82 minutes (interquartile range, -0.07-2.12 minutes), 0.28 minutes (interquartile range, -0.37-1.70 minutes), and 0.78 minutes (interquartile range, -0.02-2.10 minutes) in the HIF-1 alpha 2 x 10(9), 2 x 10(10), or 2 x 10(11) viral particle groups, respectively (P = NS between placebo and each HIF-1 alpha treatment group). There were no significant differences in claudication onset time, ankle-brachial index, or quality-of-life measurements between the placebo and each HIF-1 alpha group.Conclusions-Gene therapy with intramuscular administration of Ad2/HIF-1 alpha/VP16 is not an effective treatment for patients with intermittent claudication.

    KW - angiogenesis

    KW - gene therapy

    KW - intermittent claudication

    KW - peripheral vascular diseases

    KW - CRITICAL LIMB ISCHEMIA

    KW - ENDOTHELIAL GROWTH-FACTOR

    KW - PERIPHERAL ARTERIAL-DISEASE

    KW - DOUBLE-BLIND

    KW - TRANSCRIPTION FACTOR

    KW - FACTOR-I

    KW - ANGIOGENESIS

    KW - PLACEBO

    KW - OXYGEN

    KW - STABILIZATION

    U2 - 10.1161/CIRCULATIONAHA.110.009407

    DO - 10.1161/CIRCULATIONAHA.110.009407

    M3 - Article

    VL - 124

    SP - 1765-U148

    JO - Circulation

    JF - Circulation

    SN - 0009-7322

    IS - 16

    ER -